Amneal Pharmaceuticals Files 8-K
Ticker: AMRX · Form: 8-K · Filed: Oct 1, 2024 · CIK: 1723128
Sentiment: neutral
Topics: disclosure, sec-filing
Related Tickers: AMRX
TL;DR
Amneal dropped an 8-K, likely with important updates. Check it out.
AI Summary
Amneal Pharmaceuticals, Inc. filed an 8-K on October 1, 2024, to report information under Regulation FD and to file financial statements and exhibits. The filing does not detail specific financial figures or events but serves as a notification of these disclosures.
Why It Matters
This 8-K filing indicates that Amneal Pharmaceuticals is making disclosures to the SEC, which could include material information relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure and does not contain specific negative or positive financial news.
Key Players & Entities
- Amneal Pharmaceuticals, Inc. (company) — Registrant
- October 1, 2024 (date) — Date of earliest event reported
- 001-38485 (company) — Commission File Number
- 93-4225266 (company) — IRS Employer Identification No.
- 400 Crossing Blvd (company) — Address of principal executive offices
- Bridgewater (company) — City of principal executive offices
- NJ (company) — State of principal executive offices
- 08807 (company) — Zip code of principal executive offices
- (908) 947-3120 (company) — Registrant's telephone number
FAQ
What specific information is being disclosed in this 8-K filing?
This 8-K filing indicates disclosures under Regulation FD and the filing of financial statements and exhibits, but the specific details of these disclosures are not provided in the excerpt.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is October 1, 2024.
What is Amneal Pharmaceuticals, Inc.'s Commission File Number?
Amneal Pharmaceuticals, Inc.'s Commission File Number is 001-38485.
Where are Amneal Pharmaceuticals, Inc.'s principal executive offices located?
Amneal Pharmaceuticals, Inc.'s principal executive offices are located at 400 Crossing Blvd, Bridgewater, NJ 08807.
What is the purpose of a Form 8-K filing?
A Form 8-K is a Current Report filed with the SEC to announce major corporate events that shareholders should know about.
Filing Stats: 601 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-10-01 07:10:25
Key Financial Figures
- $0.01 — stered Class A Common Stock, par value $0.01 per share AMRX The Nasdaq Stock Market
Filing Documents
- amrx-20241001.htm (8-K) — 27KB
- amrxmetserapr_vfinal.htm (EX-99.1) — 9KB
- amrxmetserapr_vfinal001.jpg (GRAPHIC) — 261KB
- amrxmetserapr_vfinal002.jpg (GRAPHIC) — 298KB
- amrxmetserapr_vfinal003.jpg (GRAPHIC) — 33KB
- 0001628280-24-041646.txt ( ) — 979KB
- amrx-20241001.xsd (EX-101.SCH) — 2KB
- amrx-20241001_lab.xml (EX-101.LAB) — 21KB
- amrx-20241001_pre.xml (EX-101.PRE) — 12KB
- amrx-20241001_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 1, 2024, Amneal Pharmaceuticals, Inc. (the "Company") issued a press release announcing its collaboration with Metsera, Inc. to develop and supply a portfolio of next-generation medicines for obesity and metabolic diseases. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. On October 1, 2024, the Company made available an investor presentation titled "Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases" through the Investor Relations section of its website (https://investors.amneal.com/investor-relations/default.aspx). Representatives of the Company will use the presentation in various meetings with investors from time to time. In accordance with General Instruction B.2 of Form 8-K, the information referenced under Item 7.01 of this report is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report. The information found on, or otherwise accessible through, the Company's website is not incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibits are furnished herewith: Exhibit No. Description 99.1 Press release issued October 1, 2024 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 1, 2024 AMNEAL PHARMACEUTICALS, INC. By: /s/ Anastasios Konidaris Name: Anastasios Konidaris Title: Executive Vice President and Chief Financial Officer